Extra-ocular muscle cells from patients with Graves' ophthalmopathy secrete α (CXCL10) and β (CCL2) chemokines under the influence of cytokines that are modulated by PPARγ

Autoimmunity Reviews

Volumn 13, Issue 11, 2014, Pages 1160-1166

  Antonelli, Alessandro ^a   Ferrari, Silvia Martina ^a   Corrado, Alda ^a   Franceschini, Stefano Sellari ^a   Gelmini, Stefania ^b   Ferrannini, Ele ^a   Fallahi, Poupak ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

CCL2; Chemokines; CXCL10; Extra ocular muscles; Graves' ophthalmopathy

Indexed keywords

CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PIOGLITAZONE; ROSIGLITAZONE; TUMOR NECROSIS FACTOR; CCL2 PROTEIN, HUMAN; CXCL10 PROTEIN, HUMAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

CELL CULTURE; CONCENTRATION RESPONSE; CYTOKINE RELEASE; ENDOCRINE OPHTHALMOPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRAOCULAR MUSCLE; HUMAN; INFLAMMATION; MYOBLAST; NONHUMAN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; IMMUNOLOGY; SECRETION (PROCESS); SKELETAL MUSCLE;

CHEMOKINE CCL2; CHEMOKINE CXCL10; GRAVES OPHTHALMOPATHY; HUMANS; MUSCLE, SKELETAL; MYOBLASTS; PPAR GAMMA;

EID: 84908600358     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2014.08.025     Document Type: Review

References (42)

1. Förster G., Kahaly G. Endocrine orbitopathy. Med Klin (Munich) 1998, 93:365-373.
2. Weetman A.P. Graves' disease. N Engl J Med 2000, 343:1236-1248.
3. Prummel M.F., Bakker A., Wiersinga W.M., Baldeschi L., Mourits M.P., Kendall-Taylor P., et al. Multi-center study on the characteristics and treatment strategies of patients with Graves' orbitopathy: the first European Group on Graves' Orbitopathy experience. Eur J Endocrinol 2003, 148:491-495.
4. Gerlach M., Ferbert A. Pure eye muscle involvement in endocrine orbitopathy. Eur Neurol 2008, 60:67-72.
5. Garrity J.A., Bahn R.S. Pathogenesis of Graves ophthalmopathy: implications for prediction, prevention, and treatment. Am J Ophthalmol 2006, 142:147-153.
6. Kloprogge S.J., Busuttil B.E., Frauman A.G. TSH receptor protein is selectively expressed in normal human extraocular muscle. Muscle Nerve 2005, 32:95-98.
7. Entingh-Pearsall A., Kahn C.R. Differential roles of the insulin and insulin-like growth factor-I (IGFI) receptors in response to insulin and IGF-I. J Biol Chem 2004, 279:38016-38024.
8. Lahooti H., Parmar K.R., Wall J.R. Pathogenesis of thyroid-associated ophthalmopathy: does autoimmunity against calsequestrin and collagen XII play a role?. Clin Ophthalmol 2010, 4:417-425.
9. de Haan S., Lahooti H., Morris O., Wall J.R. Epitopes, immunoglobulin classes and immunoglobulin G subclasses of calsequestrin antibodies in patients with thyroid eye disease. Autoimmunity 2010, 43:698-703.
10. Perros P., Kendall-Taylor P. Biological activity of autoantibodies from patients with thyroid-associated ophthalmopathy: in vitro effects on porcine extraocular myoblasts. Q J Med 1992, 84:691-706.
11. Hiromatsu Y., Yang D., Bednarczuk T., Miyake I., Nonaka K., Inoue Y. Cytokine profiles in eye muscle tissue and orbital fat tissue from patients with thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 2000, 85:1194-1199.
12. Hiromatsu Y., Kaku H., Miyake I., Murayama S., Soejima E. Role of cytokines in the pathogenesis of thyroid-associated ophthalmopathy. Thyroid 2002, 12:217-221.
13. Antonelli A., Ferrari S.M., Giuggioli D., Ferrannini E., Ferri C., Fallahi P. Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases. Autoimmun Rev 2014, 13:272-280.
14. Antonelli A., Ferri C., Fallahi P., Ferrari S.M., Sebastiani M., Ferrari D., et al. High values of CXCL10 serum levels in mixed cryoglobulinemia associated with hepatitis C infection. Am J Gastroenterol 2008, 103:2488-2494.
15. Antonelli A., Ferrari S.M., Frascerra S., Di Domenicantonio A., Nicolini A., Ferrari P., et al. Increase of circulating CXCL9 and CXCL11 associated with euthyroid or subclinically hypothyroid autoimmune thyroiditis. J Clin Endocrinol Metab 2011, 96:1859-1863.
16. Antonelli A., Fallahi P., Rotondi M., Ferrari S.M., Serio M., Miccoli P. Serum levels of the interferon-gamma-inducible alpha chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomy. Br J Surg 2006, 93:1226-1231.
17. Antonelli A., Rotondi M., Fallahi P., Grosso M., Boni G., Ferrari S.M., et al. Iodine-131 given for therapeutic purposes modulates differently interferon-gamma-inducible alpha-chemokine CXCL10 serum levels in patients with active Graves' disease or toxic nodular goiter. J Clin Endocrinol Metab 2007, 92:1485-1490.
18. Antonelli A., Rotondi M., Fallahi P., Ferrari S.M., Paolicchi A., Romagnani P., et al. Increase of CXC chemokine CXCL10 and CC chemokine CCL2 serum levels in normal ageing. Cytokine 2006, 34:32-38.
19. Antonelli A., Ferrari S.M., Fallahi P., Frascerra S., Santini E., Franceschini S.S., et al. Monokine induced by interferon gamma (IFNgamma) (CXCL9) and IFNgamma inducible T-cell alpha-chemoattractant (CXCL11) involvement in Graves' disease and ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. J Clin Endocrinol Metab 2009, 94:1803-1809.
20. Antonelli A., Rotondi M., Ferrari S.M., Fallahi P., Romagnani P., Franceschini S.S., et al. Interferon-gamma-inducible alpha-chemokine CXCL10 involvement in Graves' ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. J Clin Endocrinol Metab 2006, 91:614-620.
21. Dietze D., Koenen M., Röhrig K., Horikoshi H., Hauner H., Eckel J. Impairment of insulin signaling in human skeletal muscle cells by co-culture with human adipocytes. Diabetes 2002, 51:2369-2376.
22. Antonelli A., Ferrari S.M., Frascerra S., Pupilli C., Mancusi C., Metelli M.R., et al. CXCL9 and CXCL11 chemokines modulation by peroxisome proliferator-activated receptor-alpha agonists secretion in Graves' and normal thyrocytes. J Clin Endocrinol Metab 2010, 95:E413-E420.
23. Aniszewski J.P., Valyasevi R.W., Bahn R.S. Relationship between disease duration and predominant orbital T cell subset in Graves' ophthalmopathy. J Clin Endocrinol Metab 2000, 85:776-780.
24. Wakelkamp I.M., Bakker O., Baldeschi L., Wiersinga W.M., Prummel M.F. TSH-R expression and cytokine profile in orbital tissue of active vs. inactive Graves' ophthalmopathy patients. Clin Endocrinol (Oxf) 2003, 58:280-287.
25. Mahad D.J., Howell S.J., Woodroofe M.N. Expression of chemokines in the CSF and correlation with clinical disease activity in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2002, 72:498-502.
26. Forster G., Otto E., Hansen C., Ochs K., Kahaly G. Analysis of orbital T cells in thyroid-associated ophthalmopathy. Clin Exp Immunol 1998, 112:427-434.
27. De Paepe B., Creus K.K., De Bleecker J.L. Chemokines in idiopathic inflammatory myopathies. Front Biosci 2008, 13:2548-2577.
28. Feferman T., Maiti P.K., Berrih-Aknin S., Bismuth J., Bidault J., Fuchs S., et al. Overexpression of IFN-induced protein 10 and its receptor CXCR3 in myasthenia gravis. J Immunol 2005, 174:5324-5331.
29. Raju R., Vasconcelos O., Granger R., Dalakas M.C. Expression of IFN-gamma-inducible chemokines in inclusion body myositis. J Neuroimmunol 2003, 141:125-131.
30. Crescioli C., Squecco R., Cosmi L., Sottili M., Gelmini S., Borgogni E., et al. Immunosuppression in cardiac graft rejection: a human in vitro model to study the potential use of new immunomodulatory drugs. Exp Cell Res 2008, 314:1337-1350.
31. Hiromatsu Y., Fukazawa H., How J., Wall J.R. Antibody-dependent cell-mediated cytotoxicity against human eye muscle cells and orbital fibroblasts in Graves' ophthalmopathy-roles of class II MHC antigen expression and gamma-interferon action of effector and target cells. Clin Exp Immunol 1987, 70:593-603.
32. Antonelli A., Ferri C., Fallahi P., Ferrari S.M., Giuggioli D., Colaci M., et al. CXCL10 (alpha) and CCL2 (beta) chemokines in systemic sclerosis-a longitudinal study. Rheumatology (Oxford) 2008, 47:45-49.
33. Antonelli A., Ferrari S.M., Fallahi P., Piaggi S., Paolicchi A., Franceschini S.S., et al. Cytokines (interferon-γ and tumor necrosis factor-α)-induced nuclear factor-κB activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone. Metabolism 2011, 60:277-283.
34. Chen M.H., Chen M.H., Liao S.L., Chang T.C., Chuang L.M. Role of macrophage infiltration in the orbital fat of patients with Graves' ophthalmopathy. Clin Endocrinol (Oxf) 2008, 69:332-337.
35. Hwang C.J., Afifiyan N., Sand D., Naik V., Said J., Pollock S.J., et al. Orbital fibroblasts from patients with thyroid-associated ophthalmopathy overexpress CD40: CD154 hyperinduces IL-6, IL-8, and MCP-1. Invest Ophthalmol Vis Sci 2009, 50:2262-2268.
36. van Steensel L., Paridaens D., Dingjan G.M., van Daele P.L., van Hagen P.M., Kuijpers R.W., et al. Platelet-derived growth factor-BB: a stimulus for cytokine production by orbital fibroblasts in Graves' ophthalmopathy. Invest Ophthalmol Vis Sci 2010, 51:1002-1007.
37. De Rossi M., Bernasconi P., Baggi F., de Waal Malefyt R., Mantegazza R. Cytokines and chemokines are both expressed by human myoblasts: possible relevance for the immune pathogenesis of muscle inflammation. Int Immunol 2000, 12:1329-1335.
38. Lee J.H., Woo J.H., Woo S.U., Kim K.S., Park S.M., Joe E.H., et al. The 15-deoxy-delta 12,14-prostaglandin J2 suppresses monocyte chemoattractant protein-1 expression in IFN-gamma-stimulated astrocytes through induction of MAPK phosphatase-1. J Immunol 2008, 181:8642-8649.
39. Dasu M.R., Park S., Devaraj S., Jialal I. Pioglitazone inhibits Toll-like receptor expression and activity in human monocytes and db/db mice. Endocrinology 2009, 150:3457-3464.
40. Antonelli A., Ferrari S.M., Fallahi P., Frascerra S., Piaggi S., Gelmini S., et al. Dysregulation of secretion of CXC alpha-chemokine CXCL10 in papillary thyroid cancer: modulation by peroxisome proliferator-activated receptor-gamma agonists. Endocr Relat Cancer 2009, 16:1299-1311.
41. Graham D.J., Ouellet-Hellstrom R., MaCurdy T.E., Ali F., Sholley C., Worrall C., et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 2010, 304:411-418.
42. Moynihan R. European drug agency extends review of safety of pioglitazone. BMJ 2011, 342:d4105.